Tag Archive for: mast cell

Alys Pharmaceuticals announces CTA submission for ALY-301, the first mast cell selective c-Kit inhibitor for treatment of Cold Urticaria

/in

ALY-301 is a first-in-class bispecific antibody targeting c-Kit and CD-203c with mast cell selectivity Designed to enable safe dosing in chronic conditions and deliver clinical proof-of concept in a Phase 1/1b study Boston, Massachusetts and Lausanne, Switzerland, 10 June 2025 – Alys Pharmaceuticals, Inc. (“Alys”), an immune-dermatology focused company, today announces the submission of a […]

Read more

Granular Therapeutics to accelerate development of next-generation pipeline for treating mast cell driven diseases

/in

Clinical candidate selection finalised for lead programme targeting mast-cell driven diseases  Dermatology industry veteran Thibaud Portal, PhD appointed as CEO   London, UK, March 30, 2023 – Granular Therapeutics, (Granular) a private biotech company specialising in precision biologic therapies for treating mast cell driven disorders, today announces clinical candidate selection for its lead programme which […]

Read more